ENHANCEMENT OF DISSOLUTION AND STABILITY OF CANDESARTAN CILEXETIL–LOADED SILICA POLYMERS by Khanfar, Mai et al.
 
  




MAI KHANFAR1*, BASHAR AL TAANI1, EMAN MOHAMMAD1 
1*
Email: mskhanfar@just.edu.jo  
Department of Pharmaceutical Technology, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid 22110-Jordan 
Received: 23 Oct 2018, Revised and Accepted: 09 Jan 2019 
ABSTRACT 
Objective: To prepare stable amorphous solid dispersions of candesartan cilexetil (CAN) with different types of silica, including non-porous (aerosil 
200) and porous silica (sylysia 350) using the spray-drying method. 
Methods: various ratios of candesartan cilexetil (CAN) were spray dried with aerosil and sylysia. Powder x-ray diffraction (x-ray) differential 
scanning calorimetry (DSC), SEM were used to characterize the spray dried powders in addition to dissolution and stability studies. 
Results: X-ray results showed that the spray–dried (CAN) in the prepared solid dispersion were in amorphous form irrespective of the used silica. 
In (DSC) analysis, the melting peak of spray-dried (CAN-silica) solid dispersion disappeared. Dissolution property of (CAN) was remarkably 
improved by formulating with silica particles. In comparing the effect of the type of the silica particles, the dissolution rate of (CAN) from the spray-
dried (CAN-sylysia) was faster than that (CAN-aerosil 200) irrespective of the drug content. It was also shown that the spray-dried formulation with 
silica did not recrystallize when storing at severe storage conditions (40 °C, 75% RH) for three months, while spray-dried (CAN) without silica easily 
re-crystallized under the same conditions. 
Conclusion: Spray drying of (CAN) with sylysia 350 is an efficient method to enhance the dissolution and stability of the drug. 
Keywords: Aerosil, Amorphous, Candesartan cilexetil, Solid dispersion, Spray-drying, Sylysia 




Over recent decades, many poorly water-soluble drugs have been 
developed in the pharmaceutical field; this creates one of the most 
challenging issues for the pharmaceutical industry. Candesartan 
cilexetil (CAN) is an angiotensin II-receptor blocker (ARB
intestinal epithelium
) used in 
the treatment patients with hypertension, heart failure and 
diabetic nephropathy [1]. It has a low solubility in the 
gastrointestinal fluids, which can limit its therapeutic efficacy. 
Increasing (CAN) solubility can improve its bioavailability [2]. 
Dispersion of the drug as very fine particles will increase the 
surface area available for dissolution. According to the classical 
Noyes-Whitney equation, this will increase the dissolution rate [3] 
One way to increase the surface area to improve the dissolution 
rate is by reducing the particle size using micronization. 
Alternatively, the dissolution rate of (CAN) can be improved also 
by increasing its aqueous solubility through formation of a 
cyclodextrin inclusion complex [4] or through the preparation of 
self-micro emulsifying drug delivery systems (SMEDDS) [5-7] or 
by developing (CAN)-loaded solid lipid nanoparticles (CLNs) [8, 9] 
or through formation of solid dispersion involving effective P-gp 
inhibition (P-glycoprotein—which is an efflux pump distributed 
throughout the body especially in the , and is 
responsible for limiting cellular uptake and the distribution of 
xenobiotics by pumping any them back into the intestinal lumen—
for optimal drug delivery [10, 11].  
The disadvantages of the previous methods are the complexity of 
their preparation and the use of expensive excipients. 
Another method for improving the dissolution is through 
amorphization and stabilization of the amorphous form in the drug 
product [12, 13]. The amorphous form usually has higher apparent 
solubility and improved dissolution rate compared to the crystalline 
counterpart, but it is rarely used in pharmaceutical formulation due 
to its hygroscopicity and tendency to recrystallize [14]. Common 
methods for preparation of amorphous form can be divided into two 
categories namely; solvent evaporation based methods and non-
solvent based ones [15]. 
In the pharmaceutical industry, solvent evaporation based methods 
include: spray drying [5] in which the dry powder is produced from 
liquid solutions, suspensions or slurry by rapidly atomizing the 
liquid and drying using hot gas, freeze-drying [16] also known as 
lyophilization or cryodesiccation, is a dehydration process in 
which water is frozen in the sample and then removed by 
sublimation at low temperatures, in and rapid precipitation by 
anti-solvent which is a process in which solution of the drug and 
the carrier is prepared and then different solvent (anti-solvent) 
is added to the solution and because of the high difference in 
polarity between the two solvents both the drug and the carrier 
will precipitate in the antisolvent. Then the final suspension 
containing the drug and the carrier must be filtered or 
evaporated. The non-solvent preparation methods are either by 
melting and quench cooling in which the molten drug is cooled 
down below the melting point, the degree of cooling will 
determine the molecular order of the material, where fast 
cooling results in amorphous molecules, or by milling the drug 
using different milling techniques (ball milling or cryo-milling) 
[17], in which the material is loaded into a chamber having steel 
balls then a specific rotational speed is applied, this method is 
reported to transfer crystalline drugs to their amorphous form 
thus increasing dissolution rate [18]. 
Adsorption onto the surface of silica carriers is a known method for 
improvement of the dissolution rate of poorly soluble drugs. This 
was first described in the early 1970s [19]. Recently, some 
researchers have reported the production of solid dispersions of 
drugs using spray-drying in which they suggests that the drug may 
enter into the pore channels or adsorb onto the surface of a silica 
carrier [20-22]. Takeuchi et al. [23] reported that preparation of 
solid dispersion with silica carriers by spray-drying method could 
improve the dissolution rate of tolbutamide and stabilize meta-
stable crystals in the solid dispersion particles under the severe 
storage conditions of high temperature and humidity (60 °C, 75% 
RH) [23]. Silica particles contain many silanol groups on their 
surface and can be used as a pharmaceutical excipient; they are 
regarded as safe for oral consumption [24]. Sylysia is amorphous 
silica (SiO₂·nH₂O), synthetically produced, and micronized it is 
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characterized by high porosity and chemical purity. The porous 
structure, high specific surface area, and the capacity of porous silica’s 
adsorption will influence the drug dissolution rate and improve the 
stability of amorphous drugs [25]. While aerosil 200, is a nonporous 
material made of hydrophilic fumed silica (silicon dioxide) [24]. 
In this study, two successfully prepared amorphous solid dispersions of 
(CAN) one with porous silica (sylysia 350) and the other with nonporous 
silica (aerosil 200) were prepared by the spray-drying method. 
Comparisons of the release characteristics, physicochemical properties 
and stability of the two formulations were done. The effect of the silica 
ratio to the drug on the physicochemical properties and dissolution rate 
of the prepared dispersions was also studied.  
MATERIALS AND METHODS 
Materials 
Candesartan cilexetil (CAN) was kindly donated by the Jordanian 
Pharmaceutical Manufacturing Company, Jordan. Two types of silica 
(aerosil 200, and sylysia 350, Fuji Chemical Ltd., Japan) were used as 
obtained. The properties of the carriers are shown in table 1. 
Methanol HPLC grade was obtained by Fisher, PA, America), 
polysorbate 20 (Tween 20 was obtained by ACROS Organics, Geel, 
Belgium), Deionized distilled water was used in all experiments. All 
chemicals and reagents were used as supplied without further 
modification and of analytical grade. 
 
Table 1: Physicochemical properties of silica particle 
 Porosity  Particle size (µm)* Specific surface area (m2 Pore size (nm) /g)** Pore volume (ml/g) 
Aerosil 200  non-porous 0.012 2.0 × 10 ---------- 2 -------------- 
Sylysia350 porous 3.9 3.0 × 10 21.0 2 1.6 
*The values were with mean±SD, n=3, **The values were with mean±SD, n=3 
 
Preparation of solid dispersion particles  
The solid dispersion particles of (CAN) with silica were prepared 
using the spray-drying method. One gram of (CAN) was dissolved 
in 100 ml of 35% v/v methanol in water (the solvent was prepared 
by adding water to 35 ml of methanol until the final volume reach 
100 ml and then silica was added in different ratios (1:0, 1:1, 1:3, 
1:5, 1:7).  
After ultra-sonication for five minutes, the suspension was fed to 
Büchi mini spray dryer (Model B-190, Büchi Laboratoriums-
Technik, Flawil, Switzerland) at a rate of 5 ml/min, the aspirator 
was set at 15 and the inlet and outlet temperatures of the drying 
chamber were maintained at 85 and 60 °C, respectively. 
All dispersions were subsequently passed through a 40-mesh screen 
(425 μm) and stored in desiccators over silica gel until used for 
further analysis. 
Physicochemical characterization of solid dispersion particles 
The size of the solid dispersion particles was measured by 
Microtrac particle size analyzer (S3500, Montgomeryville, PA 
18936, USA), 2400A, Tonichi Computer, Tokyo Japan). The 
particle shape was observed by scanning electron microscopy 
(Quanta 450 FEG—USA/EEU). The specific surface area of solid 
dispersion particles was also measured by the N 2
The total amount of the loaded (CAN) was determined using UV-
9200 spectrophotometer (Rayleigh Analytical Instrument Corp., 
China). 25 mg of each sample was added to 100 ml of methanol 
as a solvent and sonicated for 15 min, then three milliliters of 
the supernatant was filtered through 0.45 µm cellulose nitrate 
membrane filter (Sartorius, Gottingen, Germany) and analyzed 
using UV-9200 spectrophotometer (Rayleigh Analytical 
Instrument Corp., China) at λ max of 245 nm. 
Determination of the drug loading efficiency (LE) 
The drug loading was determined depending on practical drug 
content previously measured and theoretical drug content that used 
in the preparation. 
 adsorption 
method (Quanta Chrome NOVA series 2000, Japan) after 
degassing the sample powder for 12 h (Flow Prep060; Shimadzu 
Co., Japan).  
The crystalline form of (CAN) in the solid dispersions was 
measured by powder X-ray diffraction method (Ultima IV X-ray 
diffractometer, Rigaku, Japan) and differential scanning 
calorimetry (DSC) (NETZSCH-DSC 204 F1 Phoenix with ASC, 
Japan). In DSC analysis, 0.5–1.0 mg of sample powder was put in 
a crimped aluminum sample pan. The increasing rate of 
temperature was 10 °C/min. 
Determination of the polymer adsorption capacity  
In order to study the silica adsorption capacity for (CAN) from 
methanol solution onto silica surface, 250 mg of (CAN) was 
dissolved in 25 ml of methanol. Then different silica (aerosil, sylysia) 
were suspended into the solution in 1:1 drug: silica ratio. The 
suspensions were stirred for 48 h and then centrifuged. Afterward 
the drug content was determined. 
Determination of the drug content 
 
The drug loading efficiency was calculated as % drug loading 
according to the following equation. 
In vitro release study 
In vitro dissolution studies were performed using USP 
dissolution apparatus II (rotating paddle). This test was 
performed in 900 ml of 0.05 M phosphate buffer (pH = 6.5) with 
0.01% tween 20 in water at 37±0.5 °C and 50 rpm [26].  
At specific time intervals (10, 20, 30, 45 and 60 min) five ml 
samples were withdrawn, filtered using a 0.45 µm cellulose 
nitrate membrane filter (Sartorius, Gottingen, Germany) and 
analyzed using UV-9200 spectrophotometer (Rayleigh Analytical 
Instrument Corp., China) at λ max of 245 nm. 
The withdrawn samples were replaced by equal volumes of fresh 
buffer media. All experiments were done in triplicate. All dilutions 
are accounted for in measurements. 
Physical stability study 
In order to evaluate the effect of temperature and humidity, 
dispersions were placed in a 25 ml vial and stored at 40 °C±2 °C and 
75%±5% relative humidity in Schutzart-Memmert, Schwabach, 
Germany) stability chamber. After three months the crystalline 
form of (CAN) in solid dispersion particles was measured by 
powder X-ray diffraction method (Ultima IV X-ray 
diffractometer, Rigaku, Japan) and differential scanning 
calorimetry (NETZSCH-DSC 204 F1 Phoenix with ASC, Japan). 
RESULTS AND DISCUSSION 
Table 2 shows the average particle size of spray-dried (CAN) and 
spray-dried (CAN-sylysi) and spray-dried (CAN-aerosil) solid 
dispersions.
 
Khanfar et al. 
Int J App Pharm, Vol 11, Issue 2, 2019, 64-70 
66 
Table 2: Particle size of solid dispersion particles with Aerosil 200 or Sylysia 
Sample CAN (raw) Spray-dried CAN CAN-aerosil 200 CAN-sylysia  
Particle size  
(µm) D50 
51.6±5.2 37.2±3.4 19.5±8.3 16.7±3.9 
Values with mean±SD, n=3. 
 
The size of all spray-dried (CAN), (CAN-sylysia) and (CAN-aerosil) 
solid dispersion was smaller than that of raw (CAN) indicating that 
the technique of spray drying have a large impact on decreasing 
particle size, The size of spray-dried (CAN-aerosil) is noticed to be 
larger than spray-dried (CAN-sylysia), this is could be due to many 
factors, firstly, sylyia although have larger particle size than aerosil, 
it has higher surface area (269 m2/g compared with 230 m2/g), but 
after spray drying, it was noticed from table 2 that particle size of 
sprayed-dried (CAN-sylysia) is the smallest compared with spray-
dried (CAN) and spray dried (CAN-aerosil) which is also aid in 
enhancing dissolution as decreasing particle size, increase surface 
area subjected to dissolution. The difference in surface area alone 
cannot account for differences in dissolution, the second major 
factor is the porosity of sylysia,due to the high porosity of sylysia, 
the drug was entrapped inside the pores to be ready for dissolution 
which is evidenced in table 2 where the surface area of spray-dried 
(CAN-sylysia) decreased from (269 m2/g to 93.1 m2/g) indicating 
loss of area due to more entrapment of the drug inside the pores, 
while the decrease in the surface area of spray dried (CAN-aerosil) 
from (230 m2/g to 171 m2
 
/g) indicating less of drug loading to the 
carriers. Similar results were observed for tolbutamide solid 
dispersion with different silica particles (sylysia 350 and aerosil 
200) prepared by the spray-drying method [23]. Table 3 shows the 
drug loading inside both carriers with different ratios of drug to 
carrier. It is observed that as the ratio of the carrier increased, the 
drug loading increase using both carriers, but it is noticed also that 
drug loading inside sylysia is much higher than inside aerosil which 
is also expected considering the porosity of sylysia. 
Table 3: Loading efficiency of the different silica polymers 
Formula Polymer used Drug ratio Average drug loaded in the dispersion±SD% (*) 
SA1 aerosil®200 1:1 49.5843±1.6113 
SA3 aerosil®200 1:3 25.4210±0.2510 
SA5 aerosil®200 1:5 16.9287±0.51331 
SA7 aerosil®200 1:7 14.0939±0.5562 
SS1 sylysia® 350 1:1 50.0607±1.6375 
SS3 sylysia® 350 1:3 23.7416±0.3320 
SS5 sylysia® 350 1:5 16.0473±0.2501 
SS7 sylysia® 350 1:7 12.9624±0.1444 
*values with mean±SD, n=3 
 
The scanning electron microscope (SEM) images of different 
dispersions are shown in (fig. (1) in the physical mixture for 
both types of silica carriers drug crystals can be clearly seen, 
while in the case of spray-dried dispersions, the images provide 
an evidence on the adsorption of the drug molecules on the 
surface of 0Tthe carrier 0T particles, which led to the destruction of 
the drug’s crystallinity, so no crystalline drug was detected but 
rather more scattered drug molecules adsorbed on the surface of 
the carrier particles, which suggest that the drug is dispersed in 
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Fig. 1: SEM of different dispersions of CAN with sylysia and aerosil at 10000 X power of magnification where (A) represents CAN (B) 
physical mixture of CAN: aerosil (C) physical mixture of CAN: sylysia 350 (D) spray-dried CAN: aerosil 200 (E) spray dried CAN: sylysia 350 
 
The powder X-ray diffraction analysis in fig. (2) and (3) clarified that 
the raw which is the (CAN) used as supplied without any treatment-is 
in the crystalline form with high-intensity diffraction peaks between 5 
and 25 (2-theta), while the spray-dried (CAN) was converted into the 
amorphous form. The change in the crystallinity of spray-dried (CAN) 
was probably because of the rapid drying rate from the drug solution. 
On the other hand, spray-dried (CAN) in solid dispersion prepared 
with silica shows a halo pattern without notable diffraction peaks 
indicating that (CAN) is in the amorphous form irrespective of the type 




Fig. 2: X-Ray diffraction of solid dispersions containing 
aerosil®200 with different ratios (a)1:1(b)1:3(c)1:5(d)1:7(e) 
amorphous CAN(f) physical mixture with (1:5) ratio and (g) 
crystalline CAN 
Fig. 3: X-Ray diffraction of solid dispersions containing 
sylysia® 350with different ratios 
(a)1:1(b)1:3(c)1:5(d)1:7(e)amorphous CAN(f) physical 
mixture with (1:5) ratio and (g) crystalline CAN 
 
Many authors reported an interaction between drug molecules and 
silanol group of silica particles [23, 27-30]. In these reports, it was 
suggested that hydrogen bonding was formed between the silanol 
groups on the surface of silica with the carbonyl group of (CAN) 
drug. In the case of porous silica (sylysia 350) and (CAN), the 
hydrogen bonding was assumed to be formed in the pores of sylysia 
and the drug molecules were entrapped there which was evidenced 
by the SEM micrographs where the drug was entrapped inside in 
addition to the surface area of data of spray-dried conjugates. This 
ensures good dispersion of the drug in the solid dispersion particles. 
DSC thermograms of raw, spray-dried (CAN) in addition to spray-
dried (CAN-aerosil) dispersions are shown in fig. (4). While those 
spray-dried dispersions of (CAN-sylysia) are shown in fig. (5). In 
both fig. the endothermic melting point of (CAN) which is expected 
to appear at 172 °C is absent, confirming the presence of the drug in 
its amorphous form as observed in the powder X-ray results. Similar 
findings were obtained by Shital Jondhale, et al. when they used the 
spray drying technique to produce amorphous dispersions of 
gliclazide with aerosil® 200 or sylysi 350 [31]
For studying the effect of loading of the drug on the release of (CAN) 
from different spray-dried solid dispersions, dissolution tests were 
done.  
. 
Fig. (6) and (7) show the dissolution profile of spray-dried (CAN-
aerosil) dispersions and spray-dried (CAN-sylysia) dispersions 
respectively. By comparing the release of spray-dried (CAN) from 
both carriers (sylysia and aerosil), it was found that the release of 
(CAN) from silica carriers in the spray-dried solid dispersions was 
remarkably higher than spray-dried (CAN) alone irrespective of the 
used silica type. This can be attributed to the improvement in 
wettability and dispersibility of the drug in the dissolution medium 
as well as the decrease in particle size and the change of the drug 
from crystalline to amorphous form and it confirms that spray-
drying of the drug alone did not give satisfactory release. 
By comparing the dissolution profiles of solid dispersion prepared 
with aerosil 200 and sylysia 350, it was found that the release of 
(CAN) from spray-dried (CAN-sylysia) solid dispersions was slightly 
faster than the release of (CAN) from spray-dried (CAN-aerosil). This 
difference may be due to the larger specific surface area of sylysia® 
350 since it is a porous polymer, having smaller particle size as 
indicated in table (2), where the particle size of spray dried (CAN-
sylysia) is (16.7±3.9 µm), while spray dried (CAN-aerosil) particle 
size is (19.5±8.3 µm). The larger surface area will increase the 
carrier adsorption capacity of the drug. The same trend was seen in 
the release of lovastatin using different silica polymers where the 
release from sylysia showed the best release compared with other 
D E 
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silica polymers which were explained due to the highest surface area 
leading to more wetting of the drug and hindering the 




Fig. 4: DSC thermogram of (a) raw CAN (b) amorphous CAN and 
solid dispersions containing Aerosil®200 with different ratios 
(c)1:1(d)1:3(e)1:5(f)1:7 and (g) aerosil® 200 
Fig. 5: DSC thermogram of (a) raw CAN (b) amorphous CAN and 
solid dispersions containing sylysia® 350 with different ratios 
(c)1:1(d)1:3(e)1:5(f)1:7 and (g) sylysia® 350 
 
  
Fig. 6: Release profile of CAN, the solid dispersions containing 
aerosil®200 SA1 (1:1), SA3 (1:3), SA5 (1:5), SA7 (1:7) and the 
corresponding physical mixture with (1:5) ratio 
 
Fig. 7: Release profile of CAN, the solid dispersions containing 
sylysia® 350, SS1 (1:1), SS3 (1:3), SS5 (1:5), SS7 (1:7) and the 
corresponding physical mixture with (1:5) ratio 
There is a difference between the two silica types when used as a 
carrier in their effect in the dissolution profile. In case of aerosil 200, 
the change in the dissolution profile was small when changing the 
drug content, and it shows a slower dissolution rate than that of 
sylysia 350 at any drug content. On the other hand, the dissolution 
profile of solid dispersion prepared with sylysia 350 was faster 
irrespective of drug content. It can be concluded that sylysia 350 
was better as a carrier to improve the dissolution property of (CAN) 
compared with aerosil 200. 
It is well known that amorphous drugs formulated in the form of 
solid dispersion tend to recrystallize on storage at high temperature 
and humidity. Therefore, the effect of aging on the performance of 
amorphous (CAN) was investigated by performing accelerated 
stability studies up to three months as per ICH guidelines 
instructions [33]. 
It has been documented that the temperature during storage 
influences the rate of recrystallization process from amorphous to 
crystalline state. Humidity during the storage period is another 
important factor affecting the re-crystallization process. The 
plasticizing effect of absorbed moisture can permit a relatively rapid 
conversion to the crystalline form due to the high mobility of the 
amorphous form leading to further instability. Thus, appropriate 
storage conditions (aging) were selected during accelerated stability 
studies to be 40 °C/75%RH. 
To test the stability of amorphous (CAN) prepared by spray drying 
method, differential scanning calorimetry (DSC) and powder X-ray 
diffraction analysis were carried out for all amorphous dispersions 
after they were stored at 40 °C and 75% humidity for three months.  
fig. (8) and (9) show the DSC results for dispersions prepared with 
aerosil® 200 and sylysia®
It is obvious from (fig. (8) that solid dispersions prepared with 
aerosil
 350, respectively. 
®
This could be attributed to larger particle size and non-porous 
characteristics of aerosil which necessitate a higher amount of 
carrier to protect the drug and keep it in the amorphous form. While 
DSC thermograms of solid dispersions prepared with sylysia
 200 are stable at high silica ratio while the dispersions 
containing 1:1 or 1:3 show an exothermic peak near 172 °C after the 
storage period which indicate that the amorphous form of the drug 
was recrystallized and transferred into a more thermodynamically 
stable form with lower dissolution properties.  
® 350 
after storage for three months demonstrate instability at 1:1 ratio; 
otherwise all dispersions were stable during the storage period as 
shown in fig. (9). 
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These results were further confirmed by X-ray analysis as seen in 
(fig. (10) and (11), the observations were inconsistent with DSC 
results, where for aerosil® 200, the dispersions containing 1:1 or 1:3 
show some diffractive peaks indicating the instability of the 
amorphous drug, while for sylysia®
 
 350 dispersions only the 
dispersion with 1:1 ratio were unstable. 
  
Fig. 8: DSC thermograms of amorphous solid dispersions containing 
aerosil®200, (a) SA1 (1:1), (b) SA3 (1:3), (c) SA5 (1:5), (d) SA7 (1:7) 
after storage for three months in the stability chamber 
Fig. 9: DSC thermograms of amorphous solid dispersions containing 
sylysia® 350, (a) SS1 (1:1), (b) SS3 (1:3), (c) SS5 (1:5), (d) SS7 (1:7) 
after storage for three months in the stability chamber 
 
  
Fig. 10: X-Ray diffraction of solid dispersions containing aerosil®200, 
(a) SA7 (1:7), (b) SA5 (1:5), (c) SA3 (1:3), (d) SA1 (1:1) and (e) 
amorphous CAN without silica after storing all samples for 3 mo in the 
stability chamber 
Fig. 11: X-Ray diffraction of solid dispersions containing 
sylysia® 350, (a) SS7 (1:7), (b) SS5 (1:5), (c) SS3 (1:3), (d) SS1 
(1:1) and (e) amorphous CAN after storing all samples for 3 mo 
in the stability chamber 
 
Compared with the amorphous spray-dried (CAN) without silica, the 
X-ray curve shows the high intensity of diffractive peaks that 
attributed to the faster crystallization process of the drug. 
CONCLUSION 
Solid dispersion particles of (CAN) with different silica carriers were 
prepared using a spray drying method. The drug crystals were 
successfully transformed into the amorphous form and an 
improvement in the dissolution rate was achieved. Comparison of 
the dissolution rate and release of CAN between spray-dried (CAN-
aerosil) and spray-dried (CAN-sylysia) it was found that the release 
of CAN from a dispersion prepared with sylysia® 350 was faster than 
dispersions prepared with aerosil®
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